MedTrace Logo

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-04-08

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Conditions

Interventions

DRUG

PLX2853 20 mg

PLX2853 tablets

DRUG

Olaparib

Olaparib tablets

DRUG

Abiraterone acetate

Abiraterone acetate tablets

DRUG

Prednisone

Prednisone (or equivalent) tablets

DRUG

PLX2853 40 mg

PLX2853 tablets

DRUG

PLX2853 80 mg

PLX2853 tablets

Sponsors & Collaborators

  • Opna Bio LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2022-05-24
Completion
2022-05-24
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04556617 on ClinicalTrials.gov